BlackRock’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-4,749,863
| Closed | -$323M | – | 5993 |
|
|
2022
Q3 | $323M | Sell |
4,749,863
-22,528
| -0.5% | -$1.24M | 0.01% | 1116 |
|
|
2022
Q2 | $152M | Sell |
4,772,391
-512,120
| -10% | -$15M | ﹤0.01% | 1733 |
|
|
2022
Q1 | $183M | Sell |
5,284,511
-68,545
| -1% | -$2.05M | ﹤0.01% | 1736 |
|
|
2021
Q4 | $157M | Sell |
5,353,056
-418,159
| -7% | -$13M | ﹤0.01% | 1909 |
|
|
2021
Q3 | $147M | Buy |
5,771,215
+983
| +0% | +$28.9K | ﹤0.01% | 1944 |
|
|
2021
Q2 | $202M | Buy |
5,770,232
+1,578,003
| +38% | +$61.6M | 0.01% | 1754 |
|
|
2021
Q1 | $171M | Buy |
4,192,229
+508,969
| +14% | +$23.4M | 0.01% | 1834 |
|
|
2020
Q4 | $160M | Buy |
3,683,260
+367,275
| +11% | +$18.1M | 0.01% | 1781 |
|
|
2020
Q3 | $183M | Sell |
3,315,985
-284,050
| -8% | -$18.1M | 0.01% | 1454 |
|
|
2020
Q2 | $227M | Sell |
3,600,035
-1,176,885
| -25% | -$80.7M | 0.01% | 1273 |
|
|
2020
Q1 | $244M | Sell |
4,776,920
-78,253
| -2% | -$5.24M | 0.01% | 1018 |
|
|
2019
Q4 | $386M | Sell |
4,855,173
-113,670
| -2% | -$6.74M | 0.01% | 998 |
|
|
2019
Q3 | $241M | Buy |
4,968,843
+486,115
| +11% | +$25.3M | 0.01% | 1269 |
|
|
2019
Q2 | $236M | Buy |
4,482,728
+205,785
| +5% | +$11.8M | 0.01% | 1305 |
|
|
2019
Q1 | $226M | Buy |
4,276,943
+50,598
| +1% | +$2.49M | 0.01% | 1328 |
|
|
2018
Q4 | $173M | Buy |
4,226,345
+40,076
| +1% | +$1.5M | 0.01% | 1419 |
|
|
2018
Q3 | $159M | Buy |
4,186,269
+43,507
| +1% | +$1.93M | 0.01% | 1642 |
|
|
2018
Q2 | $187M | Buy |
4,142,762
+898,162
| +28% | +$40.9M | 0.01% | 1507 |
|
|
2018
Q1 | $157M | Sell |
3,244,600
-75,282
| -2% | -$4.2M | 0.01% | 1539 |
|
|
2017
Q4 | $131M | Sell |
3,319,882
-207,426
| -6% | -$7.75M | 0.01% | 1682 |
|
|
2017
Q3 | $110M | Buy |
3,527,308
+122,770
| +4% | +$3.45M | 0.01% | 1804 |
|
|
2017
Q2 | $93.1M | Buy |
3,404,538
+785,691
| +30% | +$23.4M | ﹤0.01% | 1848 |
|
|
2017
Q1 | $96.5M | Buy |
2,618,847
+2,564,008
| +4,676% | +$64.6M | 0.01% | 1802 |
|
|
2016
Q4 | $792K | Buy |
54,839
+5,100
| +10% | +$89.6K | ﹤0.01% | 1574 |
|
|
2016
Q3 | $1.15M | Buy |
49,739
+775
| +2% | +$14.8K | ﹤0.01% | 1427 |
|
|
2016
Q2 | $812K | Buy |
48,964
+48,579
| +12,618% | +$980K | ﹤0.01% | 1506 |
|
|
2016
Q1 | $6K | Sell |
385
-515
| -57% | -$9.15K | ﹤0.01% | 3347 |
|
|
2015
Q4 | $29K | Sell |
900
-30,800
| -97% | -$1.33M | ﹤0.01% | 2384 |
|
|
2015
Q3 | $1.34M | Buy |
+31,700
| New | +$1.5M | ﹤0.01% | 1183 |
|
Other funds holding GBT
BlackRock's GBT Position: Q4 2022 in Review
BlackRock sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 4,749,863 shares — an estimated $323M sold.
BlackRock first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $386M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- BlackRock reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- BlackRock sold 4,749,863 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $323M.
- BlackRock first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- BlackRock's Global Blood Therapeutics, Inc. position peaked at $386M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.